Lessons Learned from CCS Demonstration and Large Pilot Projects
MeTA: Overview and lessons learned in pilot countries
-
Upload
metapresents -
Category
Health & Medicine
-
view
457 -
download
1
description
Transcript of MeTA: Overview and lessons learned in pilot countries
![Page 1: MeTA: Overview and lessons learned in pilot countries](https://reader036.fdocuments.in/reader036/viewer/2022062617/54c042994a7959ae478b47aa/html5/thumbnails/1.jpg)
Brian Elliott,
Executive Director
International MeTA Secretariat
19th May 2009
Medicines Transparency Alliance (MeTA) Overview and lessons learned in pilot countries
MeTA 08/04/2009 1
![Page 2: MeTA: Overview and lessons learned in pilot countries](https://reader036.fdocuments.in/reader036/viewer/2022062617/54c042994a7959ae478b47aa/html5/thumbnails/2.jpg)
What is MeTA?
An approach designed to support country efforts to increase access to medicines
Improve information and increase transparency on price, quality, availability and promotion
A multi-stakeholder approach to support stronger governance and more accountability
International & national – peer pressure, share learning and work at both ends of supply chain
![Page 3: MeTA: Overview and lessons learned in pilot countries](https://reader036.fdocuments.in/reader036/viewer/2022062617/54c042994a7959ae478b47aa/html5/thumbnails/3.jpg)
MeTA Principles
Commitment to improving health Comprehensive approach to health systems,
including pharmaceuticals Transparency and accountability can:
– Improve system performance– Build confidence– Support equity and social justice
Multi-stakeholder approach needed
![Page 4: MeTA: Overview and lessons learned in pilot countries](https://reader036.fdocuments.in/reader036/viewer/2022062617/54c042994a7959ae478b47aa/html5/thumbnails/4.jpg)
MeTa Country commitments
Establish an effective multi-stakeholder forum
Progressive disclosure of data in four areas
Quality Regulatory, sourcing, quality assurance, vigilance
Availability Supply chain operations, equitable access
Price Supplier, wholesaler, retailer, import taxes, duties, affordability
Promotion Objective information,rational use, ethical advertising and promotion
![Page 5: MeTA: Overview and lessons learned in pilot countries](https://reader036.fdocuments.in/reader036/viewer/2022062617/54c042994a7959ae478b47aa/html5/thumbnails/5.jpg)
MeTA Pilot Countries
![Page 6: MeTA: Overview and lessons learned in pilot countries](https://reader036.fdocuments.in/reader036/viewer/2022062617/54c042994a7959ae478b47aa/html5/thumbnails/6.jpg)
MeTA Pilot objectives
Add value to country ATM efforts through transparency and multi-stakeholder working
Road test the MeTA approach in different country settings
Engage stakeholders at country and int’l levels
Provide a model for eventual roll out in further countries
![Page 7: MeTA: Overview and lessons learned in pilot countries](https://reader036.fdocuments.in/reader036/viewer/2022062617/54c042994a7959ae478b47aa/html5/thumbnails/7.jpg)
MeTA implementation process
Stakeholders engaged
MeTA Council formed
MeTA Secretariat formed
Pre-MoU work done
MoU signed
Workstarted
GHANA
JORDAN
KYRGYZSTAN
PERU
PHILIPPINES
UGANDA
ZAMBIA
![Page 8: MeTA: Overview and lessons learned in pilot countries](https://reader036.fdocuments.in/reader036/viewer/2022062617/54c042994a7959ae478b47aa/html5/thumbnails/8.jpg)
MIAG
Specific Success or Milestone
GHANA JORDAN KYRGYZSTAN PERU PHILIPPINES UGANDA ZAMBIA
Establishment of the physical
secretariat
Full support of
government and private
sector
Identifying the stakeholders and approval of the
work plan
Sign MoU because it is
final point
Successful forums and
especially the CSO Forum in
Jan 2009
Successful launch and
the receiving of funds
Successful launch and
media interest
8
![Page 9: MeTA: Overview and lessons learned in pilot countries](https://reader036.fdocuments.in/reader036/viewer/2022062617/54c042994a7959ae478b47aa/html5/thumbnails/9.jpg)
19 05 /2009MeTA 9
Key Challenges to MeTA implementation
Stakeholder engagement and maintaining interest Insufficient legislation/regulation and excessive
bureaucracy Difficulties in extracting information Lack of tools for accessing information
![Page 10: MeTA: Overview and lessons learned in pilot countries](https://reader036.fdocuments.in/reader036/viewer/2022062617/54c042994a7959ae478b47aa/html5/thumbnails/10.jpg)
Lessons learned in countries Country contexts are varied. MeTA needs to be country-led to succeed, so
local conditions determine the timetable of the workplan and roll-out. It takes time to get the right people at the table and develop a working
relationship between stakeholders with varied and sometimes conflicting interests.
Consensus builds with a constant exchange of views. Commitment of the stakeholders is key to a successful process. Building trust is an essential part of the initiative. Some problems in the medicines supply chain require tough political action
to solve. Starting work on less controversial issues is key. Systems and structures for disclosing data often do not exist in countries
and may have to be created.
![Page 11: MeTA: Overview and lessons learned in pilot countries](https://reader036.fdocuments.in/reader036/viewer/2022062617/54c042994a7959ae478b47aa/html5/thumbnails/11.jpg)
Key priorities for MeTA Progressive disclosure of data about medicines Developing and testing a new multi-stakeholder approach
including identifying and trying to fill gaps in the MeTA Councils; preparing stakeholders for meaningful engagement
Ensuring the strong engagement of the private sector at country and international level
Increasing the voice of patients and consumers which involves strengthening capacity and opportunity for their engagement
Documenting innovation, change and good practice across the programme.
![Page 12: MeTA: Overview and lessons learned in pilot countries](https://reader036.fdocuments.in/reader036/viewer/2022062617/54c042994a7959ae478b47aa/html5/thumbnails/12.jpg)
10/04/23MeTA 12
Congratulations to Jordan on the successful establishment of MeTA and every good wish for the success of the programme.
International Secretariat, [email protected] www.MedicinesTransparency.org